10-Q: Contineum Therapeutics Q3 2025: Increased Losses Amid Pipeline Progress

Contineum Therapeutics reported increased net losses in Q3 2025 and for the nine months ended September 30, 2025, while advancing its lead drug candidates PIPE-791 and PIPE-307 with key clinical trial milestones expected.

Summary

• Net loss for the three months ended September 30, 2025, increased to $12.8 million from $10.3 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, increased to $44.8 million from $27.7 million in the same period of 2024.
• Research and development expenses rose to $11.0 million in Q3 2025 from $9.7 million in Q3 2024, and to $38.8 million for the nine months from $25.4 million in the prior year.
• General and administrative expenses increased to $3.9 million in Q3 2025 from $3.2 million in Q3 2024, and to $12.2 million for the nine months from $8.4 million in the prior year.
• Cash, cash equivalents, and marketable securities totaled $182.4 million as of September 30, 2025.
• Management believes existing capital is sufficient to fund operations for at least 12 months from October 30, 2025.
• Raised $19.0 million in net proceeds from an at-the-market (ATM) offering of 3,241,110 Class A common shares at a weighted average price of $6.04 per share during the three months ended September 30, 2025.
• PIPE-791, for Idiopathic Pulmonary Fibrosis (IPF) and chronic pain, is slated for a global Phase 2 trial in IPF in Q4 2025, and topline data from its Phase 1b chronic pain trial is expected in H1 2026.
• PIPE-307, partnered with Janssen Pharmaceutica NV (J&J), for Relapse-Remitting Multiple Sclerosis (RRMS), fully enrolled its Phase 2 VISTA trial in January 2025, with topline data expected in Q4 2025. J&J also initiated a Phase 2 trial for PIPE-307 in Major Depressive Disorder (MDD) in December 2024.

Sentiment

Score: 5

Explanation: The company reported increased net losses and operating expenses, which are negative financial indicators. However, these increases are largely driven by significant progress in its clinical pipeline, including planned and ongoing Phase 2 trials for its lead drug candidates, PIPE-791 and PIPE-307, and a strong cash position providing over 12 months of runway. The ATM offering successfully raised additional capital. The mixed financial results with clear operational progress balance the sentiment to neutral.

Positives

• Strong cash position with $182.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Successful completion of an at-the-market (ATM) offering, raising $19.0 million in net proceeds, enhancing liquidity.
• Advancement of lead asset PIPE-791 with a global Phase 2 trial in IPF planned for Q4 2025 and a Phase 1b chronic pain trial initiated in March 2025, with topline data expected in H1 2026.
• Full enrollment of the Phase 2 VISTA trial for PIPE-307 in RRMS in January 2025, with topline data anticipated in Q4 2025.
• Janssen Pharmaceutica NV (J&J) initiated a Phase 2 trial for PIPE-307 in Major Depressive Disorder (MDD) in December 2024, demonstrating continued partnership commitment and pipeline expansion.
• Management projects sufficient capital to support operations for at least 12 months from October 30, 2025.

Negatives

• Net loss increased significantly to $12.8 million for the three months ended September 30, 2025, compared to $10.3 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $44.8 million, up from $27.7 million in the prior year period.
• Research and development expenses increased by $1.3 million for the three months and $13.4 million for the nine months ended September 30, 2025, reflecting higher clinical trial and personnel costs.
• General and administrative expenses increased by $0.7 million for the three months and $3.7 million for the nine months ended September 30, 2025, due to increased personnel and public company operating costs.
• Interest income decreased by $0.7 million for the three months and $0.1 million for the nine months ended September 30, 2025, due to decreased funds invested and lower yields.
• Accumulated deficit grew to $162.2 million as of September 30, 2025.

Risks

• Uncertainty regarding the safety and efficacy of drug candidates in clinical trials.
• Potential for delays in the timing and progress of current and future clinical trials.
• Reliance on third parties, such as Janssen Pharmaceutica NV, for the clinical development of PIPE-307.
• Inability to obtain and maintain regulatory approval for drug candidates.
• Challenges in obtaining and protecting intellectual property rights, including patent terms.
• Need for additional financing through equity, debt, or commercial arrangements, with no assurance of availability on acceptable terms.
• Potential for dilution of stockholder ownership if additional capital is raised through equity sales.
• Risk of relinquishing valuable rights to technology or future revenue streams if funds are raised through licensing or other commercial arrangements.
• Competition from existing and future therapies and technologies.
• Ability to attract and retain senior management and additional qualified personnel.
• Fluctuations in net losses from quarter-to-quarter and year-to-year due to timing and scope of clinical trials and R&D expenditures.
• Market value of voting and non-voting common stock held by non-affiliates could fall below $250 million or $700 million, impacting smaller reporting company status.
• Litigation could have an adverse impact due to defense/settlement costs, diversion of management resources, negative publicity, and reputational harm.

Future Outlook

Management expects operating expenses to significantly increase as it continues to develop and seek regulatory approvals for drug candidates, expand its pipeline, grow operations and headcount, and maintain its intellectual property portfolio. The company anticipates financing operations through public/private equity or debt financings, or commercial arrangements, including milestone payments from collaborations. Existing cash, cash equivalents, and marketable securities are believed to be sufficient to meet anticipated operating expenses and capital expenditure requirements through at least the next 12 months from October 30, 2025. Topline data for the PIPE-307 Phase 2 VISTA trial is expected in Q4 2025, and a global Phase 2 trial for PIPE-791 in IPF is planned for Q4 2025. Topline data for the PIPE-791 Phase 1b chronic pain trial is anticipated in H1 2026.

Management Comments

• Management believes existing cash, cash equivalents and marketable securities will be sufficient to support its operations for at least 12 months from the issuance date of these unaudited condensed financial statements.
• We expect our operating expenses to significantly increase as we continue to develop, conduct clinical trials, and seek regulatory approvals for our drug candidates, engage in other research and development activities to expand the indications for our existing drug candidates and develop a pipeline of additional drug candidates, expand our operations and headcount, maintain and expand our intellectual property portfolio, and, if we obtain approval for one or more of our drug candidates, launch commercial activities.
• We also expect to incur additional operating expenses as we continue operating as a public company.
• We expect to finance our operations through both public and private sales of equity, debt financings or other commercial arrangements, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties.

Industry Context

Contineum Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically targeting neuroscience, inflammation, and immunology (NI&I) indications. The company's strategy of developing selective small molecule drug candidates, such as the LPA1R inhibitor PIPE-791 and the M1R selective inhibitor PIPE-307, aligns with industry trends focusing on precision medicine and addressing significant unmet medical needs. Its collaboration with Johnson & Johnson for PIPE-307 demonstrates a common industry approach to de-risk development and leverage larger partners' resources for late-stage clinical trials and commercialization. The increased R&D spending reflects the typical progression of clinical-stage biotechs as programs advance, while the reliance on equity financing and strategic partnerships is standard for companies without approved products generating revenue.

Comparison to Industry Standards

• PIPE-307 is believed to be the most advanced selective M1R antagonist in clinical development, suggesting a potential competitive advantage in this specific mechanism.
• The company's preclinical studies and Phase 1 healthy volunteer data for PIPE-791 suggest potential differentiation compared to other LPA1R antagonists due to high bioavailability, low plasma protein binding, and long receptor occupancy time.
• The collaboration model with Janssen Pharmaceutica NV (a Johnson & Johnson company) for PIPE-307 is a common strategy in the biopharmaceutical industry for clinical-stage companies to share development risks and leverage the resources and expertise of larger pharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Johnson & Johnson Innovation JJDC, Inc., an affiliate of J&J, purchased approximately 1.7 million shares of Series C convertible preferred stock at $15.00 per share for an aggregate of approximately $25.0 million in April 2023. This transaction was determined to be at fair value.

Stakeholder Impact

• Shareholders: Increased net losses and R&D expenses could impact profitability, but pipeline progress and a strong cash runway offer future potential. Dilution from the ATM offering and potential future capital raises is a consideration. Rule 10b5-1 plans by officers indicate planned sales, which could be perceived negatively.
• Employees: Increased personnel-related expenses and stock-based compensation indicate continued investment in the workforce. The 2024 Equity Incentive Plan and ESPP provide incentives and opportunities for ownership.
• Customers (future): Progress in clinical trials for PIPE-791 and PIPE-307 offers potential new therapies for patients with IPF, chronic pain, RRMS, and MDD.
• Partners (J&J): Continued collaboration on PIPE-307, with J&J initiating its own Phase 2 trial for MDD, indicates a strong ongoing partnership.
• Creditors: The company's strong cash position and projected runway mitigate immediate concerns regarding its ability to meet short-term obligations.

Next Steps

• Initiate a global Phase 2 clinical trial for PIPE-791 in Idiopathic Pulmonary Fibrosis (IPF) in the fourth quarter of 2025.
• Anticipate topline data from the PIPE-307 Phase 2 VISTA trial for Relapse-Remitting Multiple Sclerosis (RRMS) in the fourth quarter of 2025.
• Anticipate topline data from the exploratory PIPE-791 Phase 1b chronic pain trial in the first half of 2026.
• Continue to develop, conduct clinical trials, and seek regulatory approvals for drug candidates.
• Engage in other research and development activities to expand indications for existing drug candidates and develop a pipeline of additional drug candidates.
• Expand operations and headcount.
• Maintain and expand the intellectual property portfolio.
• If drug candidates are approved, launch commercial activities.
• Potentially raise additional funds through public/private equity or debt financings or other commercial arrangements.

Key Dates

Recommendation

While the company reported increased net losses and operating expenses, these are largely attributable to significant investments in advancing its clinical pipeline, which is typical for a clinical-stage biopharmaceutical company. The strong cash position of $182.4 million, bolstered by a recent ATM offering, provides a runway of at least 12 months, mitigating immediate liquidity concerns. Key catalysts are expected in Q4 2025 (PIPE-307 RRMS data, PIPE-791 IPF Phase 2 initiation) and H1 2026 (PIPE-791 chronic pain data). The collaboration with J&J for PIPE-307 also de-risks a significant portion of the pipeline. However, the increased burn rate and the inherent risks of clinical development, coupled with the planned stock sales by officers, suggest a 'hold' position until further clinical data or clearer commercialization pathways emerge. The stock is likely to be sensitive to upcoming clinical trial results.

Keywords

Contineum Therapeutics, CTNM, biopharmaceutical, neuroscience, inflammation, immunology, NI&I, PIPE-791, PIPE-307, LPA1R inhibitor, M1R inhibitor, idiopathic pulmonary fibrosis, IPF, chronic pain, multiple sclerosis, MS, relapse-remitting multiple sclerosis, RRMS, major depressive disorder, MDD, clinical trials, Phase 2, Phase 1b, Janssen Pharmaceutica, Johnson & Johnson, SEC filing, 10-Q, biotech, drug development, clinical-stage